Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: hypoxia inducible factor targeting therapies - Janssen Pharmaceuticals

Next Previous
Search
Drug Profile

Research programme: hypoxia inducible factor targeting therapies - Janssen Pharmaceuticals

Alternative Names: AKB 5169; JNJ 5169

Latest Information Update: 21 Mar 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Pharmaceutica
  • Class Anti-inflammatories
  • Mechanism of Action Hypoxia inducible factor 1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Inflammatory bowel diseases

Most Recent Events

  • 28 Mar 2021 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in USA (PO)
  • 28 Mar 2018 Akebia Therapeutics has issued and pending patents for AKB 5169 composition of matter, pharmaceutical compositions, and methods of treatment in USA and additional patents issued or pending in countries worldwide
  • 28 Mar 2018 Akebia Therapeutics announces intention to submit IND to the US FDA for Inflammatory bowel disease in 2018

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top